Lincoln W. Pasquina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lincoln W. Pasquina has a total of 241 co-authors. Here are the top co-authors by number of shared publications:
- Ryon P. Graf
Foundation Medicine, Cambridge, Massachusetts
62 shared publications - Geoffrey R. Oxnard
Eli Lilly and Company, Indianapolis, Indiana
40 shared publications - Merrida Childress
Foundation Medicine (United States) 9
37 shared publications - Christopher J. Sweeney
South Australian Immunogenomics Cancer Institute, University of Adelaide, Adelaide, Australia
36 shared publications - Chang Xu
Foundation Medicine, Inc., Boston, MA, USA
35 shared publications - David Fabrizio
Foundation Medicine Inc, Boston, Massachusetts, USA
35 shared publications
Latest Publications
- 28 October 2026
- Published by Elsevier in The Lancet Oncology
Talazoparib plus enzalutamide versus placebo plus enzalutamide in metastatic androgen pathway modulator-resistant (castration-resistant) prostate cancer (TALAPRO-2): a biomarker analysis of circulating tumour DNA and cells for prognosis and molecular profiling
- 28 October 2026
- Published by Elsevier in The Lancet Oncology
Talazoparib plus enzalutamide versus placebo plus enzalutamide in metastatic androgen pathway modulator-resistant (castration-resistant) prostate cancer (TALAPRO-2): a biomarker analysis of circulating tumour DNA and cells for prognosis and molecular profiling
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Role of ctDNA Tumor Fraction in Selecting Immunotherapy-Based Regimens in Advanced Non–Small Cell Lung Cancer
Oncoplot showing main molecular alteration according to tumor fraction (TF), metabolic tumor volume (tMTV), liver and brain mutations, age and gender
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Role of ctDNA Tumor Fraction in Selecting Immunotherapy-Based Regimens in Advanced Non–Small Cell Lung Cancer
Oncoplot showing main molecular alteration according to tumor fraction (TF), metabolic tumor volume (tMTV), liver and brain mutations, age and gender
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Role of ctDNA Tumor Fraction in Selecting Immunotherapy-Based Regimens in Advanced Non–Small Cell Lung Cancer
Correlation between bTMB and tTMB was assessed in a limited number of patients (N = 125) in the CGDB with available tissue sequencing results.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Role of ctDNA Tumor Fraction in Selecting Immunotherapy-Based Regimens in Advanced Non–Small Cell Lung Cancer
Correlation between bTMB and tTMB was assessed in a limited number of patients (N = 125) in the CGDB with available tissue sequencing results.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Role of ctDNA Tumor Fraction in Selecting Immunotherapy-Based Regimens in Advanced Non–Small Cell Lung Cancer
Baseline clinical characteristics of patients included in Flatiron HealthFoundation Medicine NSCLC clinico-genomic database (FH-FMI CGDB) study according PD-L1 known or unknown.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Role of ctDNA Tumor Fraction in Selecting Immunotherapy-Based Regimens in Advanced Non–Small Cell Lung Cancer
Baseline clinical characteristics of patients included in Flatiron HealthFoundation Medicine NSCLC clinico-genomic database (FH-FMI CGDB) study according PD-L1 known or unknown.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Role of ctDNA Tumor Fraction in Selecting Immunotherapy-Based Regimens in Advanced Non–Small Cell Lung Cancer
Baseline clinical characteristics of patients included in Flatiron HealthFoundation Medicine NSCLC clinico-genomic database (FH-FMI CGDB) study according to treatment received (ICB monotherapy vs combination with chemotherapy).
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Role of ctDNA Tumor Fraction in Selecting Immunotherapy-Based Regimens in Advanced Non–Small Cell Lung Cancer
Baseline clinical characteristics of patients included in Flatiron HealthFoundation Medicine NSCLC clinico-genomic database (FH-FMI CGDB) study according to treatment received (ICB monotherapy vs combination with chemotherapy).
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Role of ctDNA Tumor Fraction in Selecting Immunotherapy-Based Regimens in Advanced Non–Small Cell Lung Cancer
Baseline clinical characteristics of patients included in Flatiron HealthFoundation Medicine Clinico-Genomic Database (FH-FMI CGDB) by trichotomized ctDNA TF
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Role of ctDNA Tumor Fraction in Selecting Immunotherapy-Based Regimens in Advanced Non–Small Cell Lung Cancer
Baseline clinical characteristics of patients included in Flatiron HealthFoundation Medicine Clinico-Genomic Database (FH-FMI CGDB) by trichotomized ctDNA TF
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Role of ctDNA Tumor Fraction in Selecting Immunotherapy-Based Regimens in Advanced Non–Small Cell Lung Cancer
Baseline clinical characteristics of patients included in STING study for cutoff validation according to treatment received (ICB monotherapy vs combination with chemotherapy) and according to TF ≥ 5% vs TF < 5
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Role of ctDNA Tumor Fraction in Selecting Immunotherapy-Based Regimens in Advanced Non–Small Cell Lung Cancer
Baseline clinical characteristics of patients included in STING study for cutoff validation according to treatment received (ICB monotherapy vs combination with chemotherapy) and according to TF ≥ 5% vs TF < 5
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Role of ctDNA Tumor Fraction in Selecting Immunotherapy-Based Regimens in Advanced Non–Small Cell Lung Cancer
Kaplan Meyer curves for rwOS for patients treated with immunotherapy single agent (A) or in combination (B). Multivariate models for immunotherapy single agent (C) and combination (D)
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Role of ctDNA Tumor Fraction in Selecting Immunotherapy-Based Regimens in Advanced Non–Small Cell Lung Cancer
Kaplan Meyer curves for rwOS for patients treated with immunotherapy single agent (A) or in combination (B). Multivariate models for immunotherapy single agent (C) and combination (D)
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Role of ctDNA Tumor Fraction in Selecting Immunotherapy-Based Regimens in Advanced Non–Small Cell Lung Cancer
Forest plot showing multivariable models for Progression Free Survival (PFS, left) and Overall Survival (OS, right) in patients with Tumor Fraction (TF) < 1% (A-B), 1-10% (C-D) and ≥ 10% (E-F) in the FH-FMI CGDB cohort.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Role of ctDNA Tumor Fraction in Selecting Immunotherapy-Based Regimens in Advanced Non–Small Cell Lung Cancer
Forest plot showing multivariable models for Progression Free Survival (PFS, left) and Overall Survival (OS, right) in patients with Tumor Fraction (TF) < 1% (A-B), 1-10% (C-D) and ≥ 10% (E-F) in the FH-FMI CGDB cohort.